Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311558 · ClinicalTrials.gov registry record · Phase 1
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
A Phase 1 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00311558 is a Phase 1 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 18 participants.
The verdict
NCT00311558, a Phase 1 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon may interfere with the growth of cancer cells. Giving sodium stibogluconate together with interferon may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of sodium stibogluconate when given together with interferon in treating patients with advanced solid tumors, lymphoma, or myeloma.
Interventions
- BIOLOGICAL recombinant interferon alfa-2b
- DRUG sodium stibogluconate
- DRUG SSG & interferon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311558
The ClinicalTrials.gov registry entry for NCT00311558 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which recombinant interferon alfa-2b is the first listed.
NCT00311558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00311558 about?
NCT00311558 is a clinical study titled "Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma". RATIONALE: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon may interfere with the growth of cancer cells. Giving sodium stibogluconate together with interferon may kill more cancer cells. PURPOSE: This phase I trial is stu...
What is the current status of trial NCT00311558?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00311558?
The interventions under investigation include: recombinant interferon alfa-2b (BIOLOGICAL), sodium stibogluconate (DRUG), SSG & interferon (DRUG).
Who is sponsoring clinical trial NCT00311558?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.